Ocugen, Inc. (OCGN)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$1.03+$0.0300 (+3.00%) on the dayAs of the close; data may be delayed.
OCGN price, last 12 months
Key stats
- Previous close
- $1.00
- Open
- $1.01
- Day range
- $1.01 – $1.09
- 52-week range
- $0.9700 – $2.73
- Volume
- 8.3M
- Avg volume (20 days)
- 8.7M
- Market cap
- $345.9M
Performance
1W−2.8%
1M−27.0%
3M−31.3%
6M−47.5%
YTD−23.7%
1Y−37.2%
vs S&P 500, 1Y−54.0 pts
Technicals and fundamentals
About Ocugen, Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $345.9M